Stephens Raises Health Catalyst (NASDAQ:HCAT) Price Target to $9.00

Health Catalyst (NASDAQ:HCAT) had its target price boosted by Stephens from $7.00 to $9.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Several other analysts have also recently commented on the company. Citigroup increased their target price on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. increased their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Evercore ISI boosted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Piper Sandler dropped their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.71.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $7.65 on Thursday. The stock’s fifty day simple moving average is $8.16 and its 200 day simple moving average is $7.22. Health Catalyst has a one year low of $5.42 and a one year high of $11.41. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.22) earnings per share. On average, equities analysts anticipate that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Health Catalyst

In related news, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The trade was a 5.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,068 shares of company stock worth $257,555. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HCAT. First Light Asset Management LLC lifted its holdings in Health Catalyst by 438.5% during the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after acquiring an additional 3,221,408 shares in the last quarter. Millennium Management LLC lifted its stake in Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after buying an additional 1,184,131 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in shares of Health Catalyst during the first quarter worth $8,780,000. Nepsis Inc. boosted its stake in Health Catalyst by 67.9% in the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after purchasing an additional 851,448 shares during the period. Finally, Fred Alger Management LLC bought a new position in Health Catalyst during the 3rd quarter worth about $6,858,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.